- Home
- MHD vs PHAR Comparison
MHD vs PHAR Comparison
Compare MHD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHD
- PHAR
- Stock Information
- Founded
- MHD N/A
- PHAR 1988
- Country
- MHD United States
- PHAR Netherlands
- Employees
- MHD N/A
- PHAR N/A
- Industry
- MHD Investment Bankers/Brokers/Service
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MHD Finance
- PHAR Health Care
- Exchange
- MHD Nasdaq
- PHAR Nasdaq
- Market Cap
- MHD 620.5M
- PHAR 679.0M
- IPO Year
- MHD N/A
- PHAR N/A
- Fundamental
- Price
- MHD $11.96
- PHAR $9.98
- Analyst Decision
- MHD
- PHAR Strong Buy
- Analyst Count
- MHD 0
- PHAR 3
- Target Price
- MHD N/A
- PHAR $27.00
- AVG Volume (30 Days)
- MHD 124.9K
- PHAR 5.9K
- Earning Date
- MHD 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- MHD 4.16%
- PHAR N/A
- EPS Growth
- MHD N/A
- PHAR N/A
- EPS
- MHD N/A
- PHAR N/A
- Revenue
- MHD N/A
- PHAR $285,745,000.00
- Revenue This Year
- MHD N/A
- PHAR $20.08
- Revenue Next Year
- MHD N/A
- PHAR $9.22
- P/E Ratio
- MHD N/A
- PHAR N/A
- Revenue Growth
- MHD N/A
- PHAR 30.64
- 52 Week Low
- MHD $9.92
- PHAR $6.65
- 52 Week High
- MHD $12.18
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- MHD 50.46
- PHAR 56.13
- Support Level
- MHD $11.66
- PHAR $9.37
- Resistance Level
- MHD $12.05
- PHAR $10.15
- Average True Range (ATR)
- MHD 0.14
- PHAR 0.50
- MACD
- MHD 0.04
- PHAR -0.09
- Stochastic Oscillator
- MHD 76.36
- PHAR 57.53
About MHD Blackrock MuniHoldings Fund Inc.
Blackrock Muniholdings Fund Inc is a closed-end management investment company. The fund's objective is to provide shareholders with current income exempt from U.S. federal income taxes. The company invests in Transportation, Health, Utilities, Education, Housing, and other sectors.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.